Hepatitis Monthly

Published by: Kowsar

The Liver MicroRNA Expression Profiles Associated With Chronic Hepatitis C Virus (HCV) Genotype-4 Infection: A Preliminary Study

Nadia Mohamed El-Guendy 1 , Reham Helwa 2 , Medhat Salah El-Halawany 3 , Shimaa Abdel Rahman Ali 1 , Marwa Tantawy Aly 4 , Nelly Hasan Alieldin 5 , Shawky Abdel Hamid Fouad 6 , Hany Saeid 7 and Abdel-Hady Ali Abdel-Wahab 1 , *
Authors Information
1 Department of Cancer Biology, National Cancer Institute, Cairo University, Cairo, Egypt
2 Department of Zoology, Faculty of Science, Ain Shams University, Cairo, Egypt
3 Department of Zoology, Faculty of Science, Cairo University, Cairo, Egypt
4 Research Department, Children’s Cancer Hospital, Cairo, Egypt
5 Department of Biostatistics and Cancer Epidemiology, National Cancer Institute, Cairo University, Cairo, Egypt
6 Department of Internal Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt
7 Department of General Surgery, Ain Shams University, Cairo, Egypt
Article information
  • Hepatitis Monthly: April 01, 2016, 16 (4); e33881
  • Published Online: March 20, 2016
  • Article Type: Research Article
  • Received: October 26, 2015
  • Revised: February 12, 2016
  • Accepted: February 23, 2016
  • DOI: 10.5812/hepatmon.33881

To Cite: El-Guendy N M, Helwa R, El-Halawany M S, Abdel Rahman Ali S, Tantawy Aly M, et al. The Liver MicroRNA Expression Profiles Associated With Chronic Hepatitis C Virus (HCV) Genotype-4 Infection: A Preliminary Study, Hepat Mon. 2016 ; 16(4):e33881. doi: 10.5812/hepatmon.33881.

Abstract
Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Hepatitis C. 2014;
  • 2. Hnatyszyn HJ. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antivir Ther. 2005; 10(1): 1-11[PubMed]
  • 3. Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, et al. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int. 2010; 30(9): 1259-69[DOI][PubMed]
  • 4. Sharma NK, Sherker AH. Chronic viral hepatitis Diagnosis and Therapeutics. 2009; : 33-70
  • 5. Kamal SM, Nasser IA. Hepatitis C genotype 4: What we know and what we don't yet know. Hepatology. 2008; 47(4): 1371-83[DOI][PubMed]
  • 6. Pasquinelli AE. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 2012; 13(4): 271-82[DOI][PubMed]
  • 7. Gupta A, Swaminathan G, Martin-Garcia J, Navas-Martin S. MicroRNAs, hepatitis C virus, and HCV/HIV-1 co-infection: new insights in pathogenesis and therapy. Viruses. 2012; 4(11): 2485-513[DOI][PubMed]
  • 8. Shimakami T, Yamane D, Welsch C, Hensley L, Jangra RK, Lemon SM. Base pairing between hepatitis C virus RNA and microRNA 122 3' of its seed sequence is essential for genome stabilization and production of infectious virus. J Virol. 2012; 86(13): 7372-83[DOI][PubMed]
  • 9. Yoshikawa T, Takata A, Otsuka M, Kishikawa T, Kojima K, Yoshida H, et al. Silencing of microRNA-122 enhances interferon-alpha signaling in the liver through regulating SOCS3 promoter methylation. Sci Rep. 2012; 2: 637[DOI][PubMed]
  • 10. Pan QW, Henry SD, Scholte BJ, Tilanus HW, Janssen HL, van der Laan LJ. New therapeutic opportunities for hepatitis C based on small RNA. World J Gastroenterol. 2007; 13(33): 4431-6[PubMed]
  • 11. Kwon YC, Ray RB, Ray R. Hepatitis C virus infection: establishment of chronicity and liver disease progression. Excli j. 2014; 13: 977-96[PubMed]
  • 12. Bandyopadhyay S, Friedman RC, Marquez RT, Keck K, Kong B, Icardi MS, et al. Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29: miR-29 overexpression reduces hepatitis C viral abundance in culture. J Infect Dis. 2011; 203(12): 1753-62[DOI][PubMed]
  • 13. Bhanja Chowdhury J, Shrivastava S, Steele R, Di Bisceglie AM, Ray R, Ray RB. Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A. J Virol. 2012; 86(18): 10221-5[DOI][PubMed]
  • 14. Katze MG, Fornek JL, Palermo RE, Walters KA, Korth MJ. Innate immune modulation by RNA viruses: emerging insights from functional genomics. Nat Rev Immunol. 2008; 8(8): 644-54[DOI][PubMed]
  • 15. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature. 2007; 449(7164): 919-22[DOI][PubMed]
  • 16. Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol. 2013; 10(9): 542-52[DOI][PubMed]
  • 17. Shrivastava S, Mukherjee A, Ray RB. Hepatitis C virus infection, microRNA and liver disease progression. World J Hepatol. 2013; 5(9): 479-86[DOI][PubMed]
  • 18. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996; 24(2): 289-93[DOI][PubMed]
  • 19. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009; 10(6)[DOI][PubMed]
  • 20. Chang J, Guo JT, Jiang D, Guo H, Taylor JM, Block TM. Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol. 2008; 82(16): 8215-23[DOI][PubMed]
  • 21. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science. 2005; 309(5740): 1577-81[DOI][PubMed]
  • 22. Spaniel C, Honda M, Selitsky SR, Yamane D, Shimakami T, Kaneko S, et al. microRNA-122 abundance in hepatocellular carcinoma and non-tumor liver tissue from Japanese patients with persistent HCV versus HBV infection. PLoS One. 2013; 8(10)[DOI][PubMed]
  • 23. Martin M, Herceg Z. From hepatitis to hepatocellular carcinoma: a proposed model for cross-talk between inflammation and epigenetic mechanisms. Genome Med. 2012; 4(1): 8[DOI][PubMed]
  • 24. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology. 2009; 49(4): 1098-112[DOI][PubMed]
  • 25. Choi Y, Dienes HP, Krawczynski K. Kinetics of miR-122 expression in the liver during acute HCV infection. PLoS One. 2013; 8(10)[DOI][PubMed]
  • 26. Trebicka J, Anadol E, Elfimova N, Strack I, Roggendorf M, Viazov S, et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol. 2013; 58(2): 234-9[DOI][PubMed]
  • 27. Estrabaud E, Lapalus M, Broet P, Appourchaux K, De Muynck S, Lada O, et al. Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C. J Virol. 2014; 88(11): 6394-402[DOI][PubMed]
  • 28. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med. 2009; 15(1): 31-3[DOI][PubMed]
  • 29. Roy S, Benz F, Luedde T, Roderburg C. The role of miRNAs in the regulation of inflammatory processes during hepatofibrogenesis. Hepatobiliary Surg Nutr. 2015; 4(1): 24-33[DOI][PubMed]
  • 30. Haneklaus M, Gerlic M, O'Neill LA, Masters SL. miR-223: infection, inflammation and cancer. J Intern Med. 2013; 274(3): 215-26[DOI][PubMed]
  • 31. Li S, Duan X, Li Y, Liu B, McGilvray I, Chen L. MicroRNA-130a inhibits HCV replication by restoring the innate immune response. J Viral Hepat. 2014; 21(2): 121-8[DOI][PubMed]
  • 32. Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology. 2011; 53(1): 209-18[DOI][PubMed]
  • 33. Murakami Y, Toyoda H, Tanaka M, Kuroda M, Harada Y, Matsuda F, et al. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One. 2011; 6(1)[DOI][PubMed]
  • 34. Sun B, Karin M. NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene. 2008; 27(48): 6228-44[DOI][PubMed]
  • 35. Gao Z, Dou Y, Chen Y, Zheng Y. MicroRNA roles in the NF- kappaB signaling pathway during viral infections. 2014; 2014: 436097[DOI][PubMed]
  • 36. Chen R, Alvero AB, Silasi DA, Kelly MG, Fest S, Visintin I, et al. Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells. Oncogene. 2008; 27(34): 4712-23[DOI][PubMed]
  • 37. Li T, Morgan MJ, Choksi S, Zhang Y, Kim YS, Liu ZG. MicroRNAs modulate the noncanonical transcription factor NF-kappaB pathway by regulating expression of the kinase IKKalpha during macrophage differentiation. Nat Immunol. 2010; 11(9): 799-805[DOI][PubMed]
  • 38. Jia L, Wu J, Zhang L, Chen J, Zhong D, Xu S, et al. Restoration of miR-1228* expression suppresses epithelial-mesenchymal transition in gastric cancer. PLoS One. 2013; 8(3)[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments